Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.34
STJ's Cash to Debt is ranked higher than
54% of the 481 Companies
in the Global Medical Devices industry.

( Industry Median: 2.00 vs. STJ: 0.34 )
STJ' s 10-Year Cash to Debt Range
Min: 0.01   Max: No Debt
Current: 0.34

Equity to Asset 0.40
STJ's Equity to Asset is ranked higher than
54% of the 451 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. STJ: 0.40 )
STJ' s 10-Year Equity to Asset Range
Min: 0.38   Max: 0.83
Current: 0.4

0.38
0.83
Interest Coverage 12.98
STJ's Interest Coverage is ranked higher than
53% of the 262 Companies
in the Global Medical Devices industry.

( Industry Median: 234.31 vs. STJ: 12.98 )
STJ' s 10-Year Interest Coverage Range
Min: 7.08   Max: 9999.99
Current: 12.98

7.08
9999.99
F-Score: 6
Z-Score: 3.49
M-Score: -2.69
WACC vs ROIC
11.35%
15.64%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 20.47
STJ's Operating margin (%) is ranked higher than
94% of the 465 Companies
in the Global Medical Devices industry.

( Industry Median: 5.96 vs. STJ: 20.47 )
STJ' s 10-Year Operating margin (%) Range
Min: 13.95   Max: 24.73
Current: 20.47

13.95
24.73
Net-margin (%) 17.82
STJ's Net-margin (%) is ranked higher than
94% of the 465 Companies
in the Global Medical Devices industry.

( Industry Median: 4.35 vs. STJ: 17.82 )
STJ' s 10-Year Net-margin (%) Range
Min: 2.17   Max: 17.87
Current: 17.82

2.17
17.87
ROE (%) 24.30
STJ's ROE (%) is ranked higher than
97% of the 450 Companies
in the Global Medical Devices industry.

( Industry Median: 5.07 vs. STJ: 24.30 )
STJ' s 10-Year ROE (%) Range
Min: 3.02   Max: 23.7
Current: 24.3

3.02
23.7
ROA (%) 9.74
STJ's ROA (%) is ranked higher than
91% of the 481 Companies
in the Global Medical Devices industry.

( Industry Median: 2.23 vs. STJ: 9.74 )
STJ' s 10-Year ROA (%) Range
Min: 1.65   Max: 15.43
Current: 9.74

1.65
15.43
ROC (Joel Greenblatt) (%) 42.34
STJ's ROC (Joel Greenblatt) (%) is ranked higher than
91% of the 479 Companies
in the Global Medical Devices industry.

( Industry Median: 8.65 vs. STJ: 42.34 )
STJ' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 20.24   Max: 61.91
Current: 42.34

20.24
61.91
Revenue Growth (3Y)(%) 6.60
STJ's Revenue Growth (3Y)(%) is ranked higher than
78% of the 345 Companies
in the Global Medical Devices industry.

( Industry Median: 5.00 vs. STJ: 6.60 )
STJ' s 10-Year Revenue Growth (3Y)(%) Range
Min: -0.1   Max: 21
Current: 6.6

-0.1
21
EBITDA Growth (3Y)(%) -4.60
STJ's EBITDA Growth (3Y)(%) is ranked higher than
71% of the 310 Companies
in the Global Medical Devices industry.

( Industry Median: 2.80 vs. STJ: -4.60 )
STJ' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -4.6   Max: 22.2
Current: -4.6

-4.6
22.2
EPS Growth (3Y)(%) -3.30
STJ's EPS Growth (3Y)(%) is ranked higher than
74% of the 311 Companies
in the Global Medical Devices industry.

( Industry Median: 2.20 vs. STJ: -3.30 )
STJ' s 10-Year EPS Growth (3Y)(%) Range
Min: -37   Max: 120.5
Current: -3.3

-37
120.5
» STJ's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

STJ Guru Trades in Q1 2014

Louis Moore Bacon 6,670 sh (New)
Pioneer Investments 79,135 sh (New)
Steven Cohen 369,148 sh (+1750.18%)
Jeremy Grantham 804,577 sh (+258.54%)
David Dreman 47,202 sh (+71.71%)
Paul Tudor Jones 15,868 sh (+42.94%)
Andreas Halvorsen 1,901,750 sh (+27.91%)
Joel Greenblatt Sold Out
John Buckingham 109,649 sh (-0.46%)
Bill Frels 2,098,745 sh (-0.57%)
Ken Fisher 257,270 sh (-3.78%)
Vanguard Health Care Fund 5,844,300 sh (-7.2%)
James Barrow 2,917,285 sh (-7.44%)
John Rogers 1,404,552 sh (-12.46%)
John Hussman 300,000 sh (-14.29%)
Mario Gabelli 12,400 sh (-83.06%)
» More
Q2 2014

STJ Guru Trades in Q2 2014

Joel Greenblatt 4,264 sh (New)
Jim Simons 516,013 sh (New)
Mario Gabelli 37,400 sh (+201.61%)
Jeremy Grantham 1,736,038 sh (+115.77%)
Pioneer Investments 80,823 sh (+2.13%)
Ken Fisher 260,414 sh (+1.22%)
John Buckingham 110,899 sh (+1.14%)
James Barrow 2,940,885 sh (+0.81%)
Steven Cohen 186,200 sh (unchged)
Louis Moore Bacon Sold Out
Andreas Halvorsen Sold Out
Bill Frels 2,097,512 sh (-0.06%)
John Rogers 1,220,316 sh (-13.12%)
John Hussman 250,000 sh (-16.67%)
Vanguard Health Care Fund 4,301,100 sh (-26.41%)
David Dreman 31,736 sh (-32.77%)
Paul Tudor Jones 7,593 sh (-52.15%)
» More
Q3 2014

STJ Guru Trades in Q3 2014

Ray Dalio 70,236 sh (New)
Joel Greenblatt 40,718 sh (+854.92%)
Paul Tudor Jones 24,056 sh (+216.82%)
Jim Simons 615,713 sh (+19.32%)
Jeremy Grantham 1,802,341 sh (+3.82%)
James Barrow 2,982,885 sh (+1.43%)
John Buckingham 111,888 sh (+0.89%)
John Rogers 1,227,309 sh (+0.57%)
John Hussman 250,000 sh (unchged)
Mario Gabelli 37,400 sh (unchged)
Bill Frels 2,090,259 sh (-0.35%)
David Dreman 31,333 sh (-1.27%)
Ken Fisher 255,663 sh (-1.82%)
Vanguard Health Care Fund 3,932,200 sh (-8.58%)
Steven Cohen 29,300 sh (-84.26%)
» More
Q4 2014

STJ Guru Trades in Q4 2014

Joel Greenblatt 137,476 sh (+237.63%)
Vanguard Health Care Fund 5,397,300 sh (+37.26%)
Jim Simons 744,713 sh (+20.95%)
Bill Frels 2,224,239 sh (+6.41%)
James Barrow 2,994,585 sh (+0.39%)
John Buckingham 112,006 sh (+0.11%)
Steven Cohen Sold Out
John Hussman Sold Out
John Rogers 1,219,961 sh (-0.6%)
David Dreman 30,297 sh (-3.31%)
Ken Fisher 243,188 sh (-4.88%)
Jeremy Grantham 1,695,176 sh (-5.95%)
Ray Dalio 64,136 sh (-8.69%)
Mario Gabelli 12,400 sh (-66.84%)
Paul Tudor Jones 3,452 sh (-85.65%)
» More
» Details

Insider Trades

Latest Guru Trades with STJ

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Hussman 2014-12-31 Sold Out 1.3%$56.74 - $69.95 $ 66.683%0
Vanguard Health Care Fund 2014-12-31 Add 37.26%0.22%$56.74 - $69.95 $ 66.683%5397300
Joel Greenblatt 2014-12-31 Add 237.63%0.05%$56.74 - $69.95 $ 66.683%137476
Mario Gabelli 2014-12-31 Reduce -66.84%0.01%$56.74 - $69.95 $ 66.683%12400
Ray Dalio 2014-09-30 New Buy0.03%$61.14 - $70.32 $ 66.682%70236
Joel Greenblatt 2014-09-30 Add 854.92%0.02%$61.14 - $70.32 $ 66.682%40718
Andreas Halvorsen 2014-06-30 Sold Out 0.52%$61.64 - $70.46 $ 66.683%0
Vanguard Health Care Fund 2014-06-30 Reduce -26.41%0.29%$61.64 - $70.46 $ 66.683%4301100
John Hussman 2014-06-30 Reduce -16.67%0.25%$61.64 - $70.46 $ 66.683%250000
John Rogers 2014-06-30 Reduce -13.12%0.14%$61.64 - $70.46 $ 66.683%1220316
David Dreman 2014-06-30 Reduce -32.77%0.08%$61.64 - $70.46 $ 66.683%31736
Mario Gabelli 2014-06-30 Add 201.61%0.01%$61.64 - $70.46 $ 66.683%37400
Joel Greenblatt 2014-06-30 New Buy$61.64 - $70.46 $ 66.683%4264
John Hussman 2014-03-31 Reduce -14.29%0.21%$59.4 - $68.48 $ 66.683%300000
John Rogers 2014-03-31 Reduce -12.46%0.15%$59.4 - $68.48 $ 66.683%1404552
Andreas Halvorsen 2014-03-31 Add 27.91%0.11%$59.4 - $68.48 $ 66.683%1901750
David Dreman 2014-03-31 Add 71.71%0.1%$59.4 - $68.48 $ 66.683%47202
Joel Greenblatt 2014-03-31 Sold Out 0.03%$59.4 - $68.48 $ 66.683%0
Mario Gabelli 2014-03-31 Reduce -83.06%0.02%$59.4 - $68.48 $ 66.683%12400
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 22.20
STJ's P/E(ttm) is ranked higher than
91% of the 525 Companies
in the Global Medical Devices industry.

( Industry Median: 98.30 vs. STJ: 22.20 )
STJ' s 10-Year P/E(ttm) Range
Min: 12.71   Max: 51.32
Current: 22.2

12.71
51.32
Forward P/E 15.90
STJ's Forward P/E is ranked higher than
95% of the 525 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. STJ: 15.90 )
N/A
PE(NRI) 22.00
STJ's PE(NRI) is ranked higher than
90% of the 525 Companies
in the Global Medical Devices industry.

( Industry Median: 80.70 vs. STJ: 22.00 )
STJ' s 10-Year PE(NRI) Range
Min: 12.69   Max: 51.47
Current: 22

12.69
51.47
P/B 4.50
STJ's P/B is ranked higher than
67% of the 525 Companies
in the Global Medical Devices industry.

( Industry Median: 4.20 vs. STJ: 4.50 )
STJ' s 10-Year P/B Range
Min: 2.13   Max: 7.74
Current: 4.5

2.13
7.74
P/S 3.50
STJ's P/S is ranked higher than
72% of the 525 Companies
in the Global Medical Devices industry.

( Industry Median: 3.74 vs. STJ: 3.50 )
STJ' s 10-Year P/S Range
Min: 1.84   Max: 7.13
Current: 3.5

1.84
7.13
PFCF 19.50
STJ's PFCF is ranked higher than
93% of the 525 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. STJ: 19.50 )
STJ' s 10-Year PFCF Range
Min: 9.89   Max: 41.61
Current: 19.5

9.89
41.61
POCF 16.29
STJ's POCF is ranked higher than
88% of the 525 Companies
in the Global Medical Devices industry.

( Industry Median: 73.76 vs. STJ: 16.29 )
STJ' s 10-Year POCF Range
Min: 7.91   Max: 29.61
Current: 16.29

7.91
29.61
EV-to-EBIT 21.00
STJ's EV-to-EBIT is ranked higher than
85% of the 525 Companies
in the Global Medical Devices industry.

( Industry Median: 67.21 vs. STJ: 21.00 )
STJ' s 10-Year EV-to-EBIT Range
Min: 10   Max: 34.3
Current: 21

10
34.3
PEG 73.33
STJ's PEG is ranked higher than
87% of the 525 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. STJ: 73.33 )
STJ' s 10-Year PEG Range
Min: 0.72   Max: 1154.5
Current: 73.33

0.72
1154.5
Shiller P/E 26.50
STJ's Shiller P/E is ranked higher than
93% of the 525 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. STJ: 26.50 )
STJ' s 10-Year Shiller P/E Range
Min: 14.36   Max: 71.59
Current: 26.5

14.36
71.59
Current Ratio 1.93
STJ's Current Ratio is ranked higher than
61% of the 473 Companies
in the Global Medical Devices industry.

( Industry Median: 2.59 vs. STJ: 1.93 )
STJ' s 10-Year Current Ratio Range
Min: 1.15   Max: 4.53
Current: 1.93

1.15
4.53
Quick Ratio 1.52
STJ's Quick Ratio is ranked higher than
65% of the 473 Companies
in the Global Medical Devices industry.

( Industry Median: 1.98 vs. STJ: 1.52 )
STJ' s 10-Year Quick Ratio Range
Min: 0.9   Max: 3.54
Current: 1.52

0.9
3.54
Days Inventory 171.66
STJ's Days Inventory is ranked higher than
68% of the 525 Companies
in the Global Medical Devices industry.

( Industry Median: 158.55 vs. STJ: 171.66 )
STJ' s 10-Year Days Inventory Range
Min: 146.43   Max: 297.37
Current: 171.66

146.43
297.37
Days Sales Outstanding 78.88
STJ's Days Sales Outstanding is ranked higher than
71% of the 525 Companies
in the Global Medical Devices industry.

( Industry Median: 78.72 vs. STJ: 78.88 )
STJ' s 10-Year Days Sales Outstanding Range
Min: 70.8   Max: 101.34
Current: 78.88

70.8
101.34

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.60
STJ's Dividend Yield is ranked higher than
57% of the 189 Companies
in the Global Medical Devices industry.

( Industry Median: 1.45 vs. STJ: 1.60 )
STJ' s 10-Year Dividend Yield Range
Min: 0.39   Max: 2.81
Current: 1.6

0.39
2.81
Dividend Payout 0.35
STJ's Dividend Payout is ranked higher than
88% of the 525 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. STJ: 0.35 )
STJ' s 10-Year Dividend Payout Range
Min: 0.28   Max: 0.63
Current: 0.35

0.28
0.63
Yield on cost (5-Year) 1.60
STJ's Yield on cost (5-Year) is ranked higher than
52% of the 191 Companies
in the Global Medical Devices industry.

( Industry Median: 1.60 vs. STJ: 1.60 )
STJ' s 10-Year Yield on cost (5-Year) Range
Min: 0.39   Max: 2.81
Current: 1.6

0.39
2.81
Share Buyback Rate 4.20
STJ's Share Buyback Rate is ranked higher than
98% of the 333 Companies
in the Global Medical Devices industry.

( Industry Median: -1.30 vs. STJ: 4.20 )
STJ' s 10-Year Share Buyback Rate Range
Min: 4.2   Max: -6.4
Current: 4.2

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.60
STJ's Price/DCF (Projected) is ranked higher than
94% of the 525 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. STJ: 1.60 )
STJ' s 10-Year Price/DCF (Projected) Range
Min: 0.89   Max: 5.51
Current: 1.6

0.89
5.51
Price/Median PS Value 1.00
STJ's Price/Median PS Value is ranked higher than
80% of the 525 Companies
in the Global Medical Devices industry.

( Industry Median: 1.32 vs. STJ: 1.00 )
STJ' s 10-Year Price/Median PS Value Range
Min: 0.57   Max: 2.04
Current: 1

0.57
2.04
Earnings Yield (Greenblatt) 4.80
STJ's Earnings Yield (Greenblatt) is ranked higher than
85% of the 477 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. STJ: 4.80 )
STJ' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.9   Max: 10
Current: 4.8

2.9
10
Forward Rate of Return (Yacktman) 4.56
STJ's Forward Rate of Return (Yacktman) is ranked higher than
78% of the 218 Companies
in the Global Medical Devices industry.

( Industry Median: 5.16 vs. STJ: 4.56 )
STJ' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 4.4   Max: 24.6
Current: 4.56

4.4
24.6

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, EW » details
Traded in other countries:JUD.Germany,
St Jude Medical, Inc., was incorporated in Minnesota in 1976. It develops, manufactures and distributes cardiovascular medical devices for the global cardiac rhythm management, cardiovascular and atrial fibrillation therapy areas and neurostimulation medical devices for the management of chronic pain. The Company's two segments are the Implantable Electronic Systems Division and the Cardiovascular and Ablation Technologies Division. The Company's principal products in each business unit are as follows: Implantable Electronic Systems Division (IESD) - tachycardia implantable cardioverter defibrillator systems (ICDs), bradycardia pacemaker systems (pacemakers) and neurostimulation products (spinal cord and deep brain stimulation devices); and Cardiovascular and Ablation Technologies Division (CATD) - vascular products (vascular closure products, pressure measurement guidewires, optical coherence tomography (OCT) imaging products, vascular plugs and other vascular accessories), structural heart products (heart valve replacement and repair products and structural heart defect devices) and atrial fibrillation (AF) products (electrophysiology (EP) introducers and catheters, advanced cardiac mapping, navigation and recording systems and ablation systems). Implantable Electronic Systems Division (IESD): IESD is focused on the cardiac rhythm management and neuromodulation therapy areas. Cardiac rhythm management devices include ICDs that provide life-saving therapy to patients suffering from lethal heart conditions, such as sudden cardiac arrest; cardiac resynchronization therapy (CRT) devices to save and improve the lives of patients suffering from heart failure (HF); pacemakers to help patients whose hearts beat too slowly or who suffer from other debilitating cardiac arrhythmias; leads (wires that connect devices to the heart) to carry electrical impulses to the heart and provide information from the heart to the device; and programmers and remote monitoring equipment which are used by physicians and healthcare professionals to program is cardiac rhythm management devices and analyze device data to improve patient management. Neuromodulation product offerings provide neurostimulation treatment in which an implantable device delivers electrical current directly to targeted nerve sites. The Company's commercialized neurostimulation therapies include spinal cord stimulation (SCS) for the treatment of chronic pain, deep brain stimulation (DBS) for treating the symptoms of Parkinson's disease and peripheral nerve stimulation (PNS) for the treatment of chronic migraine headache. A neurostimulation system typically consists of four components: a pulse generator that produces the electrical current and is implanted under the patient's skin; implanted leads that carry the electrical impulses to the targeted nerve sites; an external patient remote control that enables the patient to control his or her therapy within prescribed ranges; and an ext
» More Articles for STJ

Headlines

Articles On GuruFocus.com
Reversing a Declining Pattern in Earnings Per Share Feb 24 2015 
Medtronic Q3 Earnings 2015 Exceeds Market Expectations Feb 19 2015 
Stocks Clocking Record Dividend Hike Feb 17 2015 
A Robust Q4 Earnings Report From Boston Scientific Feb 10 2015 
Boston Scientific Lost the First Place in Innovation Dec 11 2014 
John Rogers Ariel Appreciation Fund Q3 Commentary Oct 25 2014 
EW: Potential for Capital Appreciation Oct 03 2014 
No More a Simple Distributor Sep 07 2014 
What Drives St. Jude Medical to Be More Diversified? Apr 30 2014 
Weekly 52-Week Highs Highlight: PPG, STJ, V, LLTC, LUV Dec 23 2013 

More From Other Websites
St. Jude Medical to Present at the Barclays Global Healthcare Conference Feb 27 2015
St. Jude Medical to Present at the Barclays Global Healthcare Conference Feb 27 2015
ST JUDE MEDICAL INC Files SEC form 10-K, Annual Report Feb 26 2015
Reversing a Declining Pattern in Earnings Per Share Feb 24 2015
St. Jude Medical raises dividend by 7.4% Feb 20 2015
St. Jude Medical Announces Increase in Quarterly Dividend Feb 20 2015
Medtronic plans new study of blood pressure-lowering device Feb 17 2015
St. Jude Medical HALO US IDE Trial Tests 15mm Heart Valves - Analyst Blog Feb 11 2015
St. Jude Ready to Beat Out Peers Feb 10 2015
Amid Alleged Pacemaker Lead Defects, Schubert Jonckheer & Kolbe LLP Investigates St. Jude Medical's... Feb 10 2015
St. Jude Medical Launches U.S. Study of the Country’s Smallest Pediatric Mechanical Heart Valve Feb 10 2015
Edwards Lifesciences Stock Jumps On Strong Guidance Feb 04 2015
Millennium Management adds new position in St. Jude Medical Feb 04 2015
St. Jude Medical Announces 2015 Annual Investor Meeting Feb 02 2015
St. Jude Q4 Earnings Meet Estimates on Modest Sales Growth - Analyst Blog Jan 28 2015
St. Jude Medical (STJ) Earnings Report: Q4 2014 Conference Call Transcript Jan 28 2015
St. Jude outlook lower on foreign exchange impact Jan 28 2015
St. Jude outlook lower on foreign exchange impact Jan 28 2015
St. Jude meets 4Q profit forecasts Jan 28 2015
St. Jude meets 4Q profit forecasts Jan 28 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK